Lupin Expands U.S. Portfolio With FDA-Approved Sugammadex
MUMBAI, India and NAPLES, Fla., July 31, 2026 Lupin Limited has received approval from the U.S. Food and Drug...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
MUMBAI, India and NAPLES, Fla., July 31, 2026 Lupin Limited has received approval from the U.S. Food and Drug...
MUMBAI, India & NAPLES, Fla., USA, March 31, 2026 Lupin Limited has received tentative approval from the U.S. Food...
